Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Warren E. Buffett, 2008
Allayannis, George (Yiorgos)Caso DARDEN-F-1550-EFinanzasIn January 2008, in the midst of the subprime-mortgage crisis, Warren Buffett is looking for good investment opportunities for his almost $50 billion in cash. As usual, he has been patient and careful in identifying the right opportunities; however, the amount of cash in his company has grown considerably, and with so much cash sitting idle, returns could suffer. This case can be used to pursue several objectives: (1) to showcase Warren Buffett’s...Desde 8,20 €
-
Warren E. Buffett, 2008 - Teaching Note
Allayannis, George (Yiorgos)Nota del Instructor DARDEN-F-1550TN-EFinanzasTeaching note for product F-1550Desde 0,00 €
-
Comergent Technologies Inc.: Enterprise E-Commerce, Teaching Note
Rangan, V. Kasturi; Bellfor, MarieNota del Instructor HBS-507087-EMarketingTeaching Note to (505-016). An abstract is not available for this product.Desde 0,00 €
-
MetLife Meets Insurtech App to App
Allayannis, George (Yiorgos); Fernstrom, Aaron; Holtz, PaulCaso DARDEN-F-1947-EFinanzasThis case examines the key issues facing MetLife, a major company in life and annuity (L&A) and - to a lesser extent - property and casualty (P&C) insurance. The case provides an opportunity to analyze the business models of insurance companies, the main risks they face, and the broad investment strategies they pursue. The case also discusses how technology (including insurtech), regulation, and risk affect MetLife and insurance companies in gene...Desde 8,20 €
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Caso HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Desde 8,20 €
-
Deutsche Bank and the Road to Basel III
Allayannis, George (Yiorgos); Wicks, Andrew C.; Yemen, Gerry; Dougherty, MatthewCaso DARDEN-F-1695-EFinanzasThis public-sourced case was named the best finance case of 2013 in the 24th annual awards and competition sponsored by The Case Centre. It was designed for and works well in the latter portion of a GEMBA Financial Management and Policies course and in the early stage of a second-year MBA elective Financial Institutions and Markets course. The case is set in mid-2012 as the new co-CEOs of Deutsche Bank are about to speak in an analyst call. Stude...Desde 8,20 €
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCaso HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Desde 8,20 €
-
New Leaders of Financial Giants: The Cases of Vikram Pandit (Citi) and John Thain (Merrill Lynch)
Allayannis, George (Yiorgos)Caso DARDEN-F-1551-EFinanzasIn January 2008, Citi and Merrill Lynch are trying to steer their ships back to calm waters. The new CEOs, Vikram Pandit (Citi) and John Thain (Merrill), have been at the helm of their companies for less than three months. This case focuses on their steps to counteract the massive losses resulting from their firms' investments in subprime-mortgage structures. What actions have these leaders taken thus far and what actions should they consider goi...Desde 8,20 €
-
De Egghead a Egghead.com (A)
Rangan, V. Kasturi; Bell, MarieCaso HBS-507S15MarketingEn el transcurso de 12 meses en 1997 y 1998, Cerebrito alta dirección decidió cerrar sus 180 tiendas al por menor de ladrillo y mortero y se mueven a una tienda de electrónica. El caso describe la evolución de ese proceso, y el papel de su director general George Orban, y plantea preguntas sobre la viabilidad futura de la empresa.Desde 8,20 €
-
Fintech, Payments Innovation, and the Acquisition of Worldpay
Allayannis, George (Yiorgos); Yemen, Gerry; Lane, DavidCaso DARDEN-F-1829-EFinanzasThis case uses the Vantiv, a US credit-card-processing company, acquisition of Worldpay, Britain’s largest payments processor, to discuss broader themes in the payment space. Payments are a crucial function of financial institutions because of their sheer volume and revenue potential. Fintech has enabled more ways for financial institutions and consumers to make payments and has the potential for significant disruption. The material in the case a...Desde 8,20 €